We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PREMIER Biosoft Announces Collaboration with University of Utah
News

PREMIER Biosoft Announces Collaboration with University of Utah

PREMIER Biosoft Announces Collaboration with University of Utah
News

PREMIER Biosoft Announces Collaboration with University of Utah

Read time:
 

PREMIER Biosoft has announced that it has entered into a formal collaboration with the University of Utah to provide advanced mass spectrometry data analysis solutions for metabolomics and lipidomics.

Under the alliance, PREMIER Biosoft will work closely with the Metabolomics, Mass Spectrometry & Proteomics Core Facility at the University of Utah to power research in small molecules. Dr. James Cox, who heads the facility and currently serves as a Research Assistant Professor of Biochemistry & Core Director will work with PREMIER Biosoft to render more accurate data analysis using the experimental data and digital signatures observed. He has over 16 years of experience in MS arena with a Ph.D in Medicinal and Pharmaceutical Chemistry.

The University's core is equipped with a dozen high-performance mass spectrometers and provides expert mass spectrometry based consultation services for a broad range of research to various scientific communities.

Dr. Cox will offer his expertise by generating volumes of high throughput MS/MS data from different instrumentation platforms to assist PREMIER Biosoft in data interpretation, heuristics and strengthening the product databases.

Dr. Cox said, “Our objective is to offer a more robust analysis architecture to the software tools which are already delivering advance and complex data analysis solutions to further research in lipidomics and metabolomics”.

“The collaboration is based on a long-standing relationship with the University and Dr. James Cox. We look forward to taking this relationship to the next level through mutually beneficial research in small molecules,” said Arun Apte, CEO at PREMIER Biosoft.

Advertisement